Baxter Return on Tangible Equity 2010-2025 | BAX
Current and historical return on tangible equity values for Baxter (BAX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Baxter Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-0.56B | $-3.37B | 15.82% |
| 2024-12-31 | $-0.65B | $-3.47B | 17.43% |
| 2024-09-30 | $0.11B | $-3.29B | -2.95% |
| 2024-06-30 | $2.48B | $-4.03B | -62.49% |
| 2024-03-31 | $2.65B | $-4.10B | -55.56% |
| 2023-12-31 | $2.66B | $-3.24B | -47.14% |
| 2023-09-30 | $2.59B | $-4.47B | -38.91% |
| 2023-06-30 | $-2.85B | $-7.26B | 37.84% |
| 2023-03-31 | $-2.46B | $-7.57B | 31.64% |
| 2022-12-31 | $-2.43B | $-7.35B | 30.48% |
| 2022-09-30 | $-2.38B | $-7.99B | 28.73% |
| 2022-06-30 | $1.01B | $-8.20B | -19.03% |
| 2022-03-31 | $1.06B | $-8.39B | -44.14% |
| 2021-12-31 | $1.28B | $-8.51B | 230.52% |
| 2021-09-30 | $1.21B | $3.84B | 33.32% |
| 2021-06-30 | $1.12B | $3.48B | 30.77% |
| 2021-03-31 | $1.07B | $3.42B | 29.51% |
| 2020-12-31 | $1.10B | $3.84B | 31.33% |
| 2020-09-30 | $0.91B | $3.83B | 26.71% |
| 2020-06-30 | $0.92B | $3.39B | 27.96% |
| 2020-03-31 | $0.99B | $3.01B | 29.67% |
| 2019-12-31 | $1.00B | $3.41B | 29.34% |
| 2019-09-30 | $1.32B | $3.41B | 38.57% |
| 2019-06-30 | $1.47B | $3.53B | 39.13% |
| 2019-03-31 | $1.50B | $3.30B | 37.61% |
| 2018-12-31 | $1.55B | $3.45B | 36.12% |
| 2018-09-30 | $1.06B | $4.73B | 23.24% |
| 2018-06-30 | $0.80B | $4.46B | 17.19% |
| 2018-03-31 | $0.72B | $4.48B | 14.82% |
| 2017-12-31 | $0.60B | $4.64B | 12.12% |
| 2017-09-30 | $1.03B | $4.97B | 20.82% |
| 2017-06-30 | $0.91B | $5.31B | 18.53% |
| 2017-03-31 | $1.86B | $4.95B | 39.24% |
| 2016-12-31 | $4.97B | $4.57B | 105.02% |
| 2016-09-30 | $4.93B | $4.81B | 102.83% |
| 2016-06-30 | $4.80B | $4.60B | 106.16% |
| 2016-03-31 | $3.92B | $4.93B | 100.30% |
| 2015-12-31 | $0.97B | $4.83B | 31.69% |
| 2015-09-30 | $1.72B | $3.72B | 62.42% |
| 2015-06-30 | $2.18B | $2.15B | 91.87% |
| 2015-03-31 | $2.37B | $1.53B | 99.92% |
| 2014-12-31 | $2.50B | $3.61B | 98.27% |
| 2014-09-30 | $1.87B | $2.23B | 87.57% |
| 2014-06-30 | $1.95B | $2.13B | 102.41% |
| 2014-03-31 | $2.02B | $2.20B | 87.34% |
| 2013-12-31 | $2.01B | $1.99B | 77.39% |
| 2013-09-30 | $2.18B | $1.28B | 72.22% |
| 2013-06-30 | $2.22B | $3.76B | 60.73% |
| 2013-03-31 | $2.29B | $3.36B | 64.92% |
| 2012-12-31 | $2.33B | $3.66B | 65.04% |
| 2012-09-30 | $2.30B | $3.83B | 64.07% |
| 2012-06-30 | $2.29B | $3.26B | 61.58% |
| 2012-03-31 | $2.24B | $3.56B | 56.12% |
| 2011-12-31 | $2.22B | $3.69B | 52.85% |
| 2011-09-30 | $2.18B | $4.36B | 50.13% |
| 2011-06-30 | $2.13B | $4.37B | 49.36% |
| 2011-03-31 | $2.05B | $4.41B | 49.57% |
| 2010-12-31 | $1.42B | $4.28B | 34.94% |
| 2010-09-30 | $1.57B | $4.22B | 36.79% |
| 2010-06-30 | $1.57B | $3.66B | 35.42% |
| 2010-03-31 | $1.63B | $4.10B | 34.92% |
| 2009-12-31 | $2.21B | $5.08B | 47.32% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $14.728B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.693B | 27.62 |
| Boston Scientific (BSX) | United States | $152.679B | 38.22 |
| Stryker (SYK) | United States | $148.653B | 31.08 |
| EssilorLuxottica (ESLOY) | France | $131.422B | 0.00 |
| Medtronic (MDT) | Ireland | $115.326B | 16.35 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.666B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.744B | 25.54 |
| ResMed (RMD) | United States | $37.302B | 28.02 |
| Agilent Technologies (A) | United States | $35.020B | 22.83 |
| GE HealthCare Technologies (GEHC) | United States | $34.401B | 16.33 |
| Terumo (TRUMY) | Japan | $24.607B | 31.96 |
| Koninklijke Philips (PHG) | Netherlands | $23.139B | 16.24 |
| Insulet (PODD) | United States | $20.361B | 79.92 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.556B | 11.92 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.262B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.993B | 24.33 |
| Lantheus Holdings (LNTH) | United States | $5.626B | 14.19 |
| Perrigo (PRGO) | Ireland | $3.785B | 9.59 |
| Prestige Consumer Healthcare (PBH) | United States | $3.780B | 16.89 |
| Haemonetics (HAE) | United States | $3.628B | 16.52 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.424B | 28.45 |
| ICU Medical (ICUI) | United States | $3.253B | 23.99 |
| QuidelOrtho (QDEL) | United States | $2.052B | 14.11 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 42.26 |
| AtriCure (ATRC) | United States | $1.521B | 0.00 |
| Acuren (TIC) | United States | $1.395B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.389B | 31.24 |
| Phibro Animal Health (PAHC) | United States | $1.248B | 15.96 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Neogen (NEOG) | United States | $1.170B | 14.97 |
| BioLife Solutions (BLFS) | United States | $1.050B | 0.00 |
| InMode (INMD) | Israel | $0.930B | 9.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.771B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.766B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.695B | 0.00 |
| Owens & Minor (OMI) | United States | $0.627B | 5.21 |
| Evolus (EOLS) | United States | $0.611B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.584B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.517B | 0.00 |
| Surmodics (SRDX) | United States | $0.441B | 0.00 |
| SNDL (SNDL) | Canada | $0.365B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.349B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.38 |
| Cresco Labs (CRLBF) | United States | $0.323B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.298B | 0.00 |
| Quanterix (QTRX) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.47 |
| Sanara MedTech (SMTI) | United States | $0.258B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.83 |
| ZimVie (ZIMV) | United States | $0.251B | 11.39 |
| Verano Holdings (VRNOF) | United States | $0.235B | 0.00 |
| Brainsway (BWAY) | Israel | $0.233B | 61.55 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Biote (BTMD) | United States | $0.223B | 6.28 |
| Omeros (OMER) | United States | $0.214B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| High Tide (HITI) | Canada | $0.191B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.93 |
| Vireo Growth (VREOF) | United States | $0.163B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.122B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| MacroGenics (MGNX) | United States | $0.102B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.68 |
| Jushi Holdings (JUSHF) | United States | $0.090B | 0.00 |
| Veru (VERU) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.081B | 0.00 |
| Apyx Medical (APYX) | United States | $0.079B | 0.00 |
| Agape ATP (ATPC) | $0.074B | 0.00 | |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Zynex (ZYXI) | United States | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Nephros (NEPH) | United States | $0.038B | 51.43 |
| United-Guardian (UG) | United States | $0.037B | 12.89 |
| Safety Shot (SHOT) | United States | $0.034B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |